Sale of Pegzilarginase to Immedica (Details) - USD ($)		3 Months Ended		9 Months Ended
	Jul. 27, 2023	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025	Dec. 31, 2025
Disposal Group, Including Discontinued Operations [Line Items]
Proceeds from sale of in-process research and development asset				$ 70,000,000	$ 7,000,000
Gain on sale of in-process research and development asset		$ 0	$ 0	70,000,000	$ 10,000,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Global Rights to Pegzilarginase
Disposal Group, Including Discontinued Operations [Line Items]
Proceeds from sale of in-process research and development asset	$ 15,000,000.0
Contingent consideration	$ 100,000,000.0
Receivable outstanding		$ 3,000,000.0		$ 3,000,000.0		$ 3,000,000.0